Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus: Launch Of Humira Biosimilar May Boost Stock
08:00am, Monday, 09'th Jan 2023
Coherus BioSciences got its toripalimab launch delayed due to the Chinese pandemic restrictions. However, eventual launch, and especially launch of Humira and Lucentis biosimilar may boost stock.
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:01am, Wednesday, 04'th Jan 2023
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Mo
Coherus BioSciences, Inc. (CHRS) Q3 2022 Earnings Call Transcript
11:42pm, Tuesday, 08'th Nov 2022
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Marek Ciszewski - Senior Vice President, Investor Relations Denny Lanfear - C
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Monday, 12'th Sep 2022
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th A
Coherus: 2022 Is In Many Ways A Make Or Break Year
04:12pm, Wednesday, 24'th Aug 2022
Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock.
Coherus BioSciences, Inc.'s (CHRS) CEO Denny Lanfear on Q2 2022 Results - Earnings Call Transcript
12:34pm, Sunday, 07'th Aug 2022
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Marek Ciszewski – Investor Relations Denny Lanfear – Chief Executive Office
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Thursday, 04'th Aug 2022
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
04:01pm, Thursday, 28'th Jul 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after
Coherus: Will Its Chinese Gambit Fail?
03:24pm, Friday, 27'th May 2022
Coherus, an established biosim developer, partnered with a Chinese company to bring a PD-1 inhibitor to the US. However, the trial was entirely done in China.
Coherus BioSciences Management to Present at Upcoming Investor Conferences
08:45am, Tuesday, 10'th May 2022
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferenc
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2022 Earnings Call Transcript
10:59pm, Thursday, 05'th May 2022
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and Chairman Paul Reider -
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
06:48pm, Thursday, 05'th May 2022
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer
09:25am, Monday, 02'nd May 2022
The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopha
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
04:01pm, Friday, 29'th Apr 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Infor
